Who
Alison Frances Lawton
Director
Company insider
Files Form 4 as: Director, Dianthus Therapeutics; Director, X4 Pharmaceuticals; Director, Spyre Therapeutics; Director and Officer, Kaleido Biosciences; Director, Verastem; Director, CoLucid Pharmaceuticals; Director, Cubist Pharmaceuticals; Chief Operating Officer, Tempest Therapeutics.
In numbers
- Trades disclosed
- 59
- Buys
- 1
- Sells
- 0
- Bought
- $23K
- Sold
- $0
- Companies
- 8
- Companies where not an officer
- 6
- First trade
- 15 Feb 2012
- Last trade
- 21 May 2026
- Last filed
- 22 May 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 21 May 2026filed 22 May 2026 | DNTH Dianthus Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —6,090 at $0.00 | filing |
| 21 May 2026filed 22 May 2026 | DNTH Dianthus Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —6,090 at $0.00 | filing |
| 22 May 2025filed 22 May 2025 | DNTH Dianthus Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —12,500 at $0.00 | filing |
| 10 Jun 2024filed 11 Jun 2024 | XFOR X4 PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —45,000 at $0.00 | filing |
| 23 May 2024filed 28 May 2024 | DNTH Dianthus Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —11,000 at $0.00 | filing |
| 11 Sep 2023filed 13 Sep 2023 | DNTH Dianthus Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —6,500 at $0.00 | filing |
| 22 Jun 2023filed 30 Jun 2023 | SYRE Spyre Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,950,000 at $0.00 | filing |
| 13 Jun 2023filed 14 Jun 2023 | XFOR X4 PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —45,000 at $0.00 | filing |
| 28 Jun 2022filed 30 Jun 2022 | DNTH Dianthus Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 7 Jun 2022filed 10 Jun 2022 | SYRE Spyre Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —43,000 at $0.00 | filing |
| 6 Jun 2022filed 27 Jun 2022 | XFOR X4 PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —6,667 at $0.00 | filing |
| 8 Jun 2021filed 9 Jun 2021 | SYRE Spyre Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 2 Jun 2021filed 2 Jun 2021 | XFOR X4 Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | $57K6,000 at $9.50 | filing |
| 1 Jun 2021filed 3 Jun 2021 | DNTH Dianthus Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —18,188 at $0.00 | filing |
| 22 Dec 2020filed 23 Dec 2020 | DNTH Dianthus Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —36,377 at $0.00 | filing |
| 15 Dec 2020filed 17 Dec 2020 | SYRE Spyre Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —47,200 at $0.00 | filing |
| 5 Oct 2020filed 6 Oct 2020 | XFOR X4 Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —6,854 at $0.00 | filing |
| 15 Apr 2020filed 17 Apr 2020 | Kaleido Biosciencesoption or derivative | SEC FORM 4 Code A | —118,500 at $0.00 | filing |
| 28 Feb 2020filed 3 Mar 2020 | Kaleido Biosciencesoption or derivative | SEC FORM 4 Code A | —46,325 at $0.00 | filing |
| 15 Nov 2019filed 18 Nov 2019 | Kaleido Biosciencesoption or derivative | SEC FORM 4 Code A | —150,000 at $0.00 | filing |
News
Verastem (NASDAQ:VSTM) Stock Price Target Raised at MizuhoVSTM · tickerreport.com · 16 Oct 2026Verastem (NASDAQ:VSTM) Shares Gap Up – Time to Buy?VSTM · tickerreport.com · 14 Oct 2026Verastem (NASDAQ:VSTM) Stock Falls 7% – Here's What HappenedVSTM · themarketsdaily.com · 13 Oct 2026
0 headlines in the last 90 days name Alison Frances Lawton; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.